DNAtrix

Dn Atrix

Biotechnology, 2450 Holcombe BLVD Ste X, San Diego, California, 77021, United States, 11-50 Employees

dnatrix.com

  • facebook
  • twitter
  • LinkedIn

phone no Phone Number: 83********

Who is DNATRIX

DNAtrix is a privately held biotech company developing virus-driven immunotherapies to treat cancer. Its proprietary adenovirus platform is based on an engineered version of the common co...

Read More

map
  • 2450 Holcombe BLVD Ste X, San Diego, California, 77021, United States Headquarters: 2450 Holcombe BLVD Ste X, San Diego, California, 77021, United States
  • 2005 Date Founded: 2005
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $10 Million to $25 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 3829 | NAICS Code: 339112 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from DNATRIX

DNAtrix Org Chart and Mapping

Employees
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding DNAtrix

Answer: DNAtrix's headquarters are located at 2450 Holcombe BLVD Ste X, San Diego, California, 77021, United States

Answer: DNAtrix's phone number is 83********

Answer: DNAtrix's official website is https://dnatrix.com

Answer: DNAtrix's revenue is $10 Million to $25 Million

Answer: DNAtrix's SIC: 3829

Answer: DNAtrix's NAICS: 339112

Answer: DNAtrix has 11-50 employees

Answer: DNAtrix is in Biotechnology

Answer: DNAtrix contact info: Phone number: 83******** Website: https://dnatrix.com

Answer: DNAtrix is a privately held biotech company developing virus-driven immunotherapies to treat cancer. Its proprietary adenovirus platform is based on an engineered version of the common cold virus that is designed to selectively infect and kill cancer cells while leaving healthy cells unharmed. The companys lead product candidate is DNX-2401, which is expected to enter into a global pivotal Phase 3 clinical study for patients with recurrent glioblastoma. DNX-2401 is also being evaluated in a Phase 1 study for diffuse intrinsic pontine glioma, for which it has received FDA Fast Track and Rare Pediatric Disease designations. A second product candidate, DNX-2440, is entering a Phase 1 clinical study in patients with colorectal and other cancers with liver metastasis. The companys investors include Morningside Ventures and Mercury Fund.

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access